title: Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
authors.affiliation: Department of Oncology, Helsinki University Central Hospital, Helsinki.
authors.forename: C
authors.initials: C
authors.lastname: Blomqvist
authors.affiliation: Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
authors.forename: R
authors.initials: R
authors.lastname: Johansson
authors.affiliation: Department of Oncology, Helsinki University Central Hospital, Helsinki. Electronic address: maija.tarkkanen@hus.fi.
authors.forename: M
authors.initials: M
authors.lastname: Tarkkanen
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004149:Dioxoles / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000191:economics* / Q000627:therapeutic use*; D000077606:Trabectedin
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin